Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Alzheimer Res. 2014 Mar;11(3):267-73.

Rivastigmine for refractory REM behavior disorder in mild cognitive impairment.

Author information

  • 1Institute of Neurology, Catholic University, Rome, Italy. v.burnetii@gmail.com.

Abstract

BACKGROUND:

Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways.

METHODS:

We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day).

RESULTS:

RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo.

CONCLUSIONS:

Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.

PMID:
24597506
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Write to the Help Desk